z-logo
Premium
P2 nucleotide receptors in osteoclasts
Author(s) -
Naemsch Lin N.,
Du Xiaobing,
Sims Stephen M.,
Dixon S. Jeffrey
Publication year - 2001
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.1180
Subject(s) - receptor , p2y receptor , extracellular , osteoclast , intracellular , microbiology and biotechnology , bone resorption , chemistry , second messenger system , purinergic receptor , biochemistry , biology , endocrinology
Osteoclasts are large, multinucleated cells responsible for the resorption of bone and other mineralized tissues. Whereas low concentrations of extracellular ATP stimulate osteoclast formation and resorptive activity, high concentrations inhibit osteoclast formation. Cell surface receptors for nucleotides are classified into two families—P2X (ligand‐gated channels nonselective for cations) and P2Y (G‐protein‐coupled receptors linked, in most cases, to release of Ca 2+ from intracellular stores). Several subtypes of P2 receptors are expressed by mammalian osteoclasts. The P2X 4 receptor has been identified at both protein and messenger RNA levels and ATP activates a nonselective cation current with properties similar to that mediated by the cloned P2X 4 channel. The P2X 2 receptor is also expressed; however, currents with properties of P2X 2 have yet to be identified. Functional and expression studies also support the existence of the P2X 7 receptor, which is activated by high concentrations of ATP. Application of nucleotides to osteoclasts elicits transient elevation of cytosolic free Ca 2+ concentration and activation of Ca 2+ ‐dependent K + channels. Both these responses are mediated, at least in part, by release of Ca 2+ from intracellular stores, consistent with the presence of functional P2Y receptors. Expression of P2Y 1 and P2Y 2 receptors has been demonstrated in mammalian osteoclasts. The presence of multiple subtypes of P2 receptors may account for the biphasic effects of extracellular nucleotides on osteoclast function. These receptors represent potential targets for the development of novel therapeutics to inhibit bone resorption in diseases such as rheumatoid arthritis, osteoporosis, tumor‐induced osteolysis, and periodontitis. Drug Dev. Res. 53:130–139, 2001. © 2001 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here